Brazilian App Turns Patient Adoption Into a Cannabis Data Asset

LOS ANGELES- Brazil’s health-tech startup Blis says its mobile platform now supports more than 300,000 registered patients, generates roughly R$2 million (about US$363,000) in monthly revenue and reaches users in more than 1,800 municipalities. By integrating tele-consultation, ANVISA authorization under RDC 660/2022 and direct-to-patient import logistics, the company is accumulating what industry observers describe as Latin America’s largest real-world cannabis patient database, drawn from a national population of 211 million.

Analysts on LinkedIn forecast Brazil’s medical cannabis market could exceed US$4.4 billion by 2032, and report that Blis is aiming for a valuation of about US$100 million as it considers expansion into other Latin American markets and additional therapeutic categories. The firm’s anonymized clinical and purchase records position it to license data to pharmaceutical and research partners seeking real-world evidence on dosing, safety and demand.